Vertex Pharmaceuticals
VRTX
483 hedge funds and large institutions have $17.4B invested in Vertex Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 173 increasing their positions, 191 reducing their positions, and 56 closing their positions.
95.29% more ownership
Funds ownership: 0% → 95.29% (+95%)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
5% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 56
5% less call options, than puts
Call options by funds: $117M | Put options by funds: $123M
9% less repeat investments, than reductions
Existing positions increased: 173 | Existing positions reduced: 191
2% less funds holding
Funds holding: 491 → 483 (-8)
17% less capital invested
Capital invested by funds: $21B → $17.4B (-$3.59B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MNA
Manning & Napier Advisors
Fairport,
New York
|
+$161M |
| 2 |
ClearBridge Investments
New York
|
+$110M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$72.2M |
| 4 |
Two Sigma Advisers
New York
|
+$67.9M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$316M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$231M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$132M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$125M |
| 5 |
O
OppenheimerFunds
New York
|
-$83.3M |
VRTX Hedge Fund Activity: Q4 2016 in Review
483 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q4 2016, worth a combined $17.4B — down 17% from $21B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new VRTX positions and 56 closed out — a net gain of 3 holders — while 173 added to existing stakes and 191 trimmed.
The largest buyer was Manning & Napier Advisors, adding an estimated $161M. The largest seller was Jennison Associates, cutting an estimated $316M.
- 483 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q4 2016, down from 491 in Q3 2016.
- Funds reported $17.4B of Vertex Pharmaceuticals stock for Q4 2016, down 17% quarter-over-quarter.
- 59 funds opened new Vertex Pharmaceuticals positions in Q4 2016 and 56 closed out, a net change of +3 holders.
- The largest Vertex Pharmaceuticals buyer in Q4 2016 was Manning & Napier Advisors, an estimated $161M added.
- The largest Vertex Pharmaceuticals seller in Q4 2016 was Jennison Associates, an estimated $316M sold.
Based on aggregated 13F filings for Q4 2016.